PHASE I STUDY OF CYTOKINE GENE MODIFIED AUTOLOGOUS NEUROBLASTOMA CELLS FOR TREATMENT OF RELAPSED/REFRACTORY NEUROBLASTOMA USING AN ADENOVIRAL VECTOR
OBJECTIVES: I. Assess in patients with neuroblastoma the safety of up to four subcutaneous
injections of autologous neuroblastoma cells that have been modified by insertion of the
interleukin-2 (IL-2) gene introduced by an adenoviral vector. II. Determine whether major
histocompatibility complex restricted or unrestricted antitumor immune responses are induced
by treatment with IL-2 gene modified autologous neuroblasts. III. Determine the dose of IL-2
gene modified autologous neuroblasts needed to achieve antitumor responses in these
patients. IV. Obtain preliminary data on the antitumor effects of this regimen in these
patients. V. Determine the maximum tolerated dose of this regimen in these patients.
OUTLINE: This is a dose escalation study. Autologous neuroblastoma cells are modified by
insertion of the interleukin-2 (IL-2) gene introduced by an adenoviral vector. Patients
receive IL-2 gene modified autologous neuroblastoma cells subcutaneously on days 1 and 8
followed by 3-4 weeks of rest. Patients with complete or partial response or stable disease
may receive one additional course consisting of 2 additional injections separated by 1 week
at the dose level previously administered on day 8 of course 1. Patients with progressive
disease are taken off study. Cohorts of 3-6 patients receive escalating doses of IL-2 gene
modified autologous neuroblastoma cells until the maximum tolerated dose (MTD) is
determined. The MTD is defined as the dose preceding that at which 2 of 6 patients
experience dose limiting toxicity. Patients are followed every other week for 6 weeks,
monthly for 1 year, and then annually for 10 years.
PROJECTED ACCRUAL: A total of 15-24 patients will be accrued for this study over 2.5-4
years.
Interventional
Primary Purpose: Treatment
Laura C. Bowman, MD
Study Chair
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
United States: Federal Government
CDR0000064539
NCT00002713
September 1995
Name | Location |
---|---|
Saint Jude Children's Research Hospital | Memphis, Tennessee 38105-2794 |